"Discussion drafts" for FDA user fee reauthorization legislation that surfaced in the House
and Senate last week have yet to incorporate language to actually reauthorize device user fees, but do already include significant provisions to reform FDA device oversight.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?